DK3072966T3 - Mitogenaktiveret proteinkinaseafhængig rekombinant vacciniavirus (MD-RVV) og anvendelse deraf - Google Patents
Mitogenaktiveret proteinkinaseafhængig rekombinant vacciniavirus (MD-RVV) og anvendelse deraf Download PDFInfo
- Publication number
- DK3072966T3 DK3072966T3 DK14864505.4T DK14864505T DK3072966T3 DK 3072966 T3 DK3072966 T3 DK 3072966T3 DK 14864505 T DK14864505 T DK 14864505T DK 3072966 T3 DK3072966 T3 DK 3072966T3
- Authority
- DK
- Denmark
- Prior art keywords
- rvv
- mitogen
- protein kinase
- vaccinia virus
- activated protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013241299 | 2013-11-21 | ||
| PCT/JP2014/081484 WO2015076422A1 (ja) | 2013-11-21 | 2014-11-20 | 分裂促進因子活性化タンパク質キナーゼ依存性組換えワクシニアウイルス（md-rvv)及びその使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3072966T3 true DK3072966T3 (da) | 2020-03-23 |
Family
ID=53179679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14864505.4T DK3072966T3 (da) | 2013-11-21 | 2014-11-20 | Mitogenaktiveret proteinkinaseafhængig rekombinant vacciniavirus (MD-RVV) og anvendelse deraf |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9809803B2 (da) |
| EP (1) | EP3072966B1 (da) |
| JP (1) | JP6378200B2 (da) |
| KR (1) | KR102197374B1 (da) |
| CN (2) | CN105765062B (da) |
| CA (1) | CA2931294C (da) |
| DK (1) | DK3072966T3 (da) |
| WO (1) | WO2015076422A1 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10370647B2 (en) | 2015-07-22 | 2019-08-06 | National University Corporation Tottori University | Host regulatory factor that enhances replication and/or propagation of vaccinia virus |
| US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| US20190336552A1 (en) * | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
| LT3480307T (lt) | 2016-05-30 | 2021-09-27 | Astellas Pharma Inc. | Naujas genetiškai modifikuotas raupų virusas |
| EP3486322B1 (en) * | 2016-07-13 | 2021-09-29 | National University Corporation Tottori University | Method for producing vaccinia virus expressing foreign gene |
| JP7274138B2 (ja) * | 2017-11-30 | 2023-05-16 | アステラス製薬株式会社 | Ｓｃｒ欠失ワクシニアウイルス |
| JP7034818B2 (ja) * | 2018-04-19 | 2022-03-14 | Ｋｍバイオロジクス株式会社 | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 |
| CA3113965A1 (en) | 2018-09-26 | 2020-04-02 | Astellas Pharma Inc. | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
| CN109750056A (zh) * | 2019-01-07 | 2019-05-14 | 西安医学院 | 去除天坛株vgf基因的打靶质粒及其制备方法 |
| TW202038994A (zh) | 2019-01-14 | 2020-11-01 | 美商醫格耐免疫治療公司 | 重組痘瘡病毒及其使用方法 |
| CA3129883A1 (en) | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| US20220313761A1 (en) | 2019-05-14 | 2022-10-06 | National University Corporation Tottori University | Vaccinia virus that induces cell fusion and use thereof |
| CA3145907A1 (en) * | 2019-08-09 | 2021-02-18 | Toshio Murakami | Oncolytic vaccinia virus |
| AU2020337690A1 (en) | 2019-08-29 | 2022-04-07 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| JP2021106576A (ja) | 2019-12-12 | 2021-07-29 | イグナイト・イミュノセラピー，インコーポレーテッド | 変異体腫瘍溶解性ワクシニアウイルスおよびその使用法 |
| KR20220125806A (ko) | 2020-01-09 | 2022-09-14 | 화이자 인코포레이티드 | 재조합 백시니아 바이러스 |
| EP4182335A2 (en) | 2020-07-14 | 2023-05-24 | Pfizer Inc. | Recombinant vaccinia virus |
| JPWO2022107705A1 (da) | 2020-11-17 | 2022-05-27 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1180157B1 (en) | 1999-05-28 | 2012-11-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| JP4719855B2 (ja) | 2003-12-05 | 2011-07-06 | 国立大学法人北海道大学 | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター |
| JP5652830B2 (ja) | 2010-04-09 | 2015-01-14 | 国立大学法人 東京大学 | マイクロｒｎａ制御組換えワクシニアウイルス及びその使用 |
| EP2631290A4 (en) * | 2010-10-22 | 2015-06-10 | Univ Hokkaido Nat Univ Corp | VIRUS VECTOR FOR PRIME-BOOST VACCINES WITH VACCINIAVIRUS VECTORS AND SENDAIVIRUS VECTORS |
| US11149254B2 (en) * | 2011-04-15 | 2021-10-19 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| FI20115914L (fi) * | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| JP5935130B2 (ja) | 2012-05-20 | 2016-06-15 | 香蘭産業株式会社 | イネ科植物灰の製造方法 |
-
2014
- 2014-11-20 EP EP14864505.4A patent/EP3072966B1/en active Active
- 2014-11-20 WO PCT/JP2014/081484 patent/WO2015076422A1/ja active Application Filing
- 2014-11-20 CN CN201480063990.1A patent/CN105765062B/zh active Active
- 2014-11-20 DK DK14864505.4T patent/DK3072966T3/da active
- 2014-11-20 KR KR1020167016591A patent/KR102197374B1/ko active IP Right Grant
- 2014-11-20 CA CA2931294A patent/CA2931294C/en active Active
- 2014-11-20 JP JP2015549229A patent/JP6378200B2/ja active Active
- 2014-11-20 CN CN201910806504.5A patent/CN110527670A/zh active Pending
- 2014-11-20 US US15/038,145 patent/US9809803B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2931294C (en) | 2022-05-31 |
| CN105765062A (zh) | 2016-07-13 |
| WO2015076422A1 (ja) | 2015-05-28 |
| CN105765062B (zh) | 2020-12-11 |
| EP3072966A1 (en) | 2016-09-28 |
| KR102197374B1 (ko) | 2020-12-31 |
| US9809803B2 (en) | 2017-11-07 |
| KR20160079901A (ko) | 2016-07-06 |
| CN110527670A (zh) | 2019-12-03 |
| EP3072966B1 (en) | 2020-01-08 |
| CA2931294A1 (en) | 2015-05-28 |
| JPWO2015076422A1 (ja) | 2017-03-16 |
| EP3072966A4 (en) | 2017-04-19 |
| US20160281066A1 (en) | 2016-09-29 |
| JP6378200B2 (ja) | 2018-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3072966T3 (da) | Mitogenaktiveret proteinkinaseafhængig rekombinant vacciniavirus (MD-RVV) og anvendelse deraf | |
| IL276106A (en) | Garp-binding proteins and their uses | |
| DK3052516T3 (da) | PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf | |
| DK3393505T3 (da) | Rekombinante zika-vacciner | |
| DK3019533T3 (da) | Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf | |
| DK3027204T3 (da) | Flerdelte signaleringsproteiner og anvendelser deraf | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3480307T3 (da) | Ny genetisk modificeret vacciniavirus | |
| DK2951203T3 (da) | Heterodimere proteiner | |
| DK3686280T3 (da) | Carbohydratdegraderende polypeptid og anvendelser deraf | |
| DK3114145T3 (da) | Anti human interleukin-1-receptor-assessory-protein (il1rap) antistoffer og anvendelser deraf | |
| DK2970460T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| DK2968443T3 (da) | Hepcidinanaloger og anvendelser deraf | |
| DK2970464T3 (da) | Anti-lag-3-bindende proteiner | |
| DK3043784T3 (da) | Arylethere og anvendelser deraf | |
| DK2920197T3 (da) | Prolinlåste sammenhæftede peptider og anvendelser deraf | |
| DK2968418T3 (da) | Præparater afledt af placentamaterialer til fremstilling og anvendelse deraf | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3041857T3 (da) | Protein a-kromatografi | |
| DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
| DK3029038T3 (da) | Tetrazolinonforbindelse og anvendelse deraf | |
| DK3290441T3 (da) | Rgma-bindingsprotein og anvendelse deraf | |
| DK3434760T3 (da) | Fremgangsmåder til forøgelse af mannose-indholdet i rekombinante proteiner | |
| DK2983704T3 (da) | Fusionspolypeptider og vacciner | |
| DK3057979T3 (da) | Proteiner med diagnostiske og terapeutiske anvendelser |